Jan Hein Cornel

Jan Hein Cornel

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Jan Hein Cornel

Radboud University Medical Center

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PRPaul M Ridker
Paul M Ridker
BEBrendan M. Everett
Brendan M. Everett
TTTom Thuren
Tom Thuren
JMJean G. MacFadyen
Jean G. MacFadyen
WCWilliam H. Chang
William H. Chang
RGRobert J. Glynn
Robert J. Glynn
Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)

5 November 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
SNStefan M. Nidorf
Stefan M. Nidorf
AFAernoud T.L. Fiolet
Aernoud T.L. Fiolet
AMArend Mosterd
Arend Mosterd
JEJohn W. Eikelboom
John W. Eikelboom
ASAstrid Schut
Astrid Schut
PTPeter L. Thompson
Peter L. Thompson
Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary disease is limited.

1 October 2018 in The Lancet
Verified
Journal Article
Closed access
JGJennifer B Green
Jennifer B Green
SJSalim Janmohamed
Salim Janmohamed
NJNigel P Jones
Nigel P Jones
ARAnne E Rosenberg
Anne E Rosenberg
KSKristina N Sigmon
Kristina N Sigmon
TMTrisha Mandal
Trisha Mandal

29 November 2007 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JKJohn Kjekshus
John Kjekshus
EAEduard Apetrei
Eduard Apetrei
VBVivencio Barrios
Vivencio Barrios
MBMichael Böhm
Michael Böhm
JCJohn George Franklin Cleland
John George Franklin Cleland
CGCORONA Group
CORONA Group
Patients with systolic heart failure have generally been excluded from statin trials. Acute coronary events are uncommon in this population, and statins have theoretical risks in these patients.

13 December 2016 in JAMA
Verified
Journal Article
Open access
PDF file
SNStephen Nicholls
Stephen Nicholls
RPRishi Puri
Rishi Puri
TATodd Anderson
Todd Anderson
CBChristie M. Ballantyne
Christie M. Ballantyne
LCLeslie Cho
Leslie Cho
SNSteven E. Nissen
Steven E. Nissen
Reducing levels of low-density lipoprotein cholesterol (LDL-C) with inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (statins) is the cornerstone of contemporary care for patients with atherosclerotic cardiovascular disease. Analysis of data within individual statin trials and through meta-analyses suggests a consistent relationship between achieving lower LDL-C levels and reduction in major adverse cardiovascular events.1,2 In parallel, trials using intravascular ultrasound (IVUS) have studied the effect of statins on coronary atherosclerosis and demonstrated a linear relationship between achieved LDL-C levels and reduction in atheroma burden.3- 6 However, major clinical outcome trials and IVUS studies have explored a range of achieved LDL-C levels, extending to a mean of approximately 60 mg/dL.3,5

15 April 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
IGIsabelle C Van Gelder
Isabelle C Van Gelder
HGHessel F Groenveld
Hessel F Groenveld
HCHarry J G M Crijns
Harry J G M Crijns
YTYpe S Tuininga
Ype S Tuininga
JTJan G P Tijssen
Jan G P Tijssen
RIRACE II Investigators
RACE II Investigators
Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality in patients with permanent atrial fibrillation.